摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

daidzein-7-ω-carboxynonyl ether

中文名称
——
中文别名
——
英文名称
daidzein-7-ω-carboxynonyl ether
英文别名
deczein;10-(3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yloxy)decanoic acid;10-[3-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxydecanoic acid
daidzein-7-ω-carboxynonyl ether化学式
CAS
——
化学式
C25H28O6
mdl
——
分子量
424.494
InChiKey
CLHWPQYIZAZQJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.5
  • 重原子数:
    31
  • 可旋转键数:
    12
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    93.1
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    对羟基苯乙酸 、 alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾三氟化硼乙醚 作用下, 以 丙酮 为溶剂, 反应 100.5h, 生成 daidzein-7-ω-carboxynonyl ether
    参考文献:
    名称:
    The Mitochondrial Monoamine Oxidase−Aldehyde Dehydrogenase Pathway:  A Potential Site of Action of Daidzin
    摘要:
    Recent studies showed that daidzin suppresses ethanol intake in ethanol-preferring laboratory animals. In vitro, it potently and selectively inhibits the mitochondrial aldehyde dehydrogenase (ALDH-2). Further, it inhibits the conversion of monoamines such as serotonin (5-HT) and dopamine (DA) into their respective acid metabolites, 5-hydroxyindole-3-acetic acid (5-HIAA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in isolated hamster or rat liver mitochondria. Studies on the suppression of ethanol intake and inhibition of 5-HIAA (or DOPAC) formation by six structural analogues of daidzin suggested a potential link between these two activities. This, together with the finding that daidzin does not affect the rates of mitochondria-catalyzed oxidative deamination of these monoamines, raised the possibility that the ethanol intake-suppressive (antidipsotropic) action of daidzin is not mediated by the monoamines but rather by their reactive biogenic aldehyde intermediates such as 5-hydroxyindole-3-acetaldehyde (5-HIAL) and/or 3,4-dihydroxyphenylacetaldehyde (DOPAL) which accumulate in the presence of daidzin. To further evaluate this possibility, we synthesized more structural analogues of daidzin and tested and compared their antidipsotropic activities in Syrian golden hamsters with their effects on monoamine metabolism in isolated hamster liver mitochondria using 5-HT as the substrate. Effects of daidzin and its structural analogues on the activities of monoamine oxidase (MAO) and ALDH-2, the key enzymes involved in 5-HT metabolism in the mitochondria, were also examined. Results from these studies reveal a positive correlation between the antidipsotropic activities of these analogues and their abilities to increase 5-HIAL, accumulation during 5-HT metabolism in isolated hamster liver mitochondria. Daidzin analogues that potently inhibit ALDH-2 but have no or little effect on MAO are most antidipsotropic, whereas those that also potently inhibit MAO exhibit little, if any, antidipsotropic activity. These results, although inconclusive, are consistent with the hypothesis that daidzin may act via the mitochondrial MAO/ALDH pathway and that a biogenic aldehyde such as 5-HIAL may be important in mediating its antidipsotropic action.
    DOI:
    10.1021/jm990614i
点击查看最新优质反应信息

文献信息

  • Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
    申请人:——
    公开号:US20030087814A1
    公开(公告)日:2003-05-08
    Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.
    治疗、预防或减少酗酒的组合物和方法,特别是提高患者对需要摄入 ALDH 抑制剂的疗法的依从性的方法,包括施用单胺氧化酶 B 抑制剂的步骤。
  • EP1441708A4
    申请人:——
    公开号:EP1441708A4
    公开(公告)日:2007-05-23
  • COMPOSITIONS AND METHODS FOR INCREASING COMPLIANCE WITH THERAPIES USING ALDEHYDE DEHYDROGENASE INHIBITORS AND TREATING ALCOHOLISM
    申请人:Krele Pharmaceuticals LLC
    公开号:EP1441708A1
    公开(公告)日:2004-08-04
  • TREATMENT FOR COCAINE ADDICTION
    申请人:Tonix Pharmaceuticals, Inc.
    公开号:EP2611440B1
    公开(公告)日:2017-02-01
  • US8093300B2
    申请人:——
    公开号:US8093300B2
    公开(公告)日:2012-01-10
查看更多